Brain Glutamate Levels Were Lower in Cannabis Users and Linked to Craving During Abstinence

In a study of 20 cannabis users who completed 21 days of abstinence, glutamate levels in the dorsal anterior cingulate cortex were significantly lower than in controls, and decreasing glutamate correlated with increasing craving.

Zuo, Chun S et al.·Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2022·Preliminary EvidenceProspective Cohort
RTHC-04339Prospective CohortPreliminary Evidence2022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Prospective Cohort
Evidence
Preliminary Evidence
Sample
N=20

What This Study Found

dACC glutamate was significantly lower in cannabis users compared to controls from baseline through day 21 of abstinence (F=5.90, p=0.022). Changes in glutamate between baseline and day 21 had a significant negative correlation with changes in craving (r=-0.72, p=0.005). Baseline anxiety severity correlated with urinary THC levels.

Key Numbers

20 cannabis users and 10 controls completed protocol; dACC glutamate significantly lower in users (F=5.90, p=0.022); glutamate-craving correlation r=-0.72 (p=0.005); baseline anxiety correlated with THC levels (r=0.768, p=0.000076)

How They Did This

Prospective cohort study with 26 cannabis users and 11 controls (20 users and 10 controls completed 21-day verified abstinence). Dorsal anterior cingulate cortex glutamate and GABA measured with proton MRS at baseline and abstinence days 7 and 21. Cannabis withdrawal, craving, sleep, and mood measured concurrently.

Why This Research Matters

Glutamate is the brain's primary excitatory neurotransmitter and plays a key role in addiction and relapse. Finding that lower glutamate is linked to higher craving during cannabis abstinence suggests a potential target for medications that could ease withdrawal.

The Bigger Picture

Understanding the neurochemistry of cannabis withdrawal could lead to targeted medications. If glutamate levels predict craving, glutamate-modulating drugs already used for other conditions might be repurposed to help people quit cannabis.

What This Study Doesn't Tell Us

Small sample of 20 users and 10 controls limits generalizability. MRS measures glutamate in a single brain region. Cannot determine whether low glutamate is a cause or consequence of cannabis use. Non-treatment-seeking sample may differ from those seeking help to quit.

Questions This Raises

  • ?Would glutamate-modulating medications reduce cannabis craving?
  • ?Do glutamate levels recover with longer abstinence?
  • ?Is the glutamate-craving link specific to cannabis or shared across substances?

Trust & Context

Key Stat:
r = -0.72 glutamate-craving link
Evidence Grade:
Small prospective study with verified abstinence and objective brain measures, but limited sample size
Study Age:
2022 study
Original Title:
Lower dACC glutamate in cannabis users during early phase abstinence.
Published In:
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 47(11), 1969-1975 (2022)
Database ID:
RTHC-04339

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-ControlFollows or compares groups over time
This study
Cross-Sectional / Observational
Case Report / Animal Study

Enrolls participants and follows them forward in time.

What do these levels mean? →

Frequently Asked Questions

Why does low glutamate matter for cannabis withdrawal?

Glutamate is the brain's main excitatory neurotransmitter and is involved in learning, memory, and reward processing. Lower levels in cannabis users correlated with higher craving, suggesting it may play a role in the difficulty of quitting.

Do glutamate levels return to normal after quitting?

In this study, glutamate remained lower than controls through 21 days of abstinence. Whether levels eventually normalize with longer abstinence was not examined.

Read More on RethinkTHC

Cite This Study

RTHC-04339·https://rethinkthc.com/research/RTHC-04339

APA

Zuo, Chun S; Davis, Katherine A; Lukas, Scott E. (2022). Lower dACC glutamate in cannabis users during early phase abstinence.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 47(11), 1969-1975. https://doi.org/10.1038/s41386-022-01321-5

MLA

Zuo, Chun S, et al. "Lower dACC glutamate in cannabis users during early phase abstinence.." Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2022. https://doi.org/10.1038/s41386-022-01321-5

RethinkTHC

RethinkTHC Research Database. "Lower dACC glutamate in cannabis users during early phase ab..." RTHC-04339. Retrieved from https://rethinkthc.com/research/zuo-2022-lower-dacc-glutamate-in

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.